Post by Viatris on X
Viatris@ViatrisInc
XToday we announced that five abstracts from our Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference.
Learn more: t.co

11 likes1 repliesPosted Aug 1, 2025